Lipoprotein oxidation in cardiovascular disease: Chief culprit or innocent bystander?

Journal of Experimental Medicine

Volumn 203, Issue 4, 2006, Pages 813-816

  Heinecke, Jay W ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BILIVERDIN; BUTYLCRESOL; HEME OXYGENASE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; N,N' DIPHENYLPHENYLENEDIAMINE; PROBUCOL; PROBUCOL DITHIOBISPHENOL; PROBUCOL SUCCINATE; UNCLASSIFIED DRUG;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID OXIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; STRESS; UNSTABLE ANGINA PECTORIS;

CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS; OXIDATION-REDUCTION;

EID: 33645872999     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20060218     Document Type: Review

References (28)

1. Witztum, J.L., and D. Steinberg. 1991. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88:1785-1792.
2. Heinecke, J.W. 1998. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis. 141:1-15.
3. Heinecke, J.W., H. Rosen, and A. Chait. 1984. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J. Clin. Invest. 74:1890-1894.
4. Morel, D.W., P.E. DiCorleto, and G.M. Chisolm. 1984. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis. 4:357-364.
5. Steinbrecher, U.P., S. Parthasarathy, D.S. Leake, J.L. Witztum, and D. Steinberg. 1984. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. USA. 81:3883-3887.
6. Haberland, M.E., L. Cheng, and D. Fong. 1988. Malondialdehyde-altered protein occurs in atheroma of Watanabe Heritable hyperlipidemic rabbits. Science. 241:215-217.
7. Rosenfeld, M.E., W. Palinski, S. Yla-Herttuala, S. Butler, and J.L. Witztum. 1990. Distribution of oxidation specific lipid-protein adducts and apolipoprotein-B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 10:336-346.
8. Kita, T., Y. Nagano, M. Yokode, K. Ishi, N. Kume, A. Ooshima, H. Yoshida, and C. Kawai. 1987. Probucol prevents the progression of atherosclerosis in Watanabe Heritable Hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA. 84:5928-5932.
9. Carew, T.E., D.C. Schwenke, and D. Steinberg. 1987. Antiatherogenic effect of probucol unrelated to its hypercholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe Heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. USA. 84:7725-7729.
10. Parthasarathy, S., S.G. Young, J.L. Witztum, R.C. Pittman, and D. Steinberg. 1986. Probucol inhibits oxidative modification of low density lipoprotein. J. Clin. Invest. 77:641-644.
11. Wu, B.J., K. Kathir, P.K. Witting, K. Beck, K. Choy, C. Li1, K.D. Croft, T.A. Mori, D. Tanous, M.R. Adams, et al. 2006. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J. Exp. Med. 203:1117-1127.
12. Stephens, N.G., A. Parsons, P.M. Schofield, F. Kelly, K. Cheeseman, and M.J. Mitchinson. 1996. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 347:781-786.
13. 1999. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 354:447-455.
14. Yusuf, S., G. Dagenais, J. Pogue, J. Bosch, and P. Sleight. 2000. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342:154-160.
15. Lee, I.M., N.R. Cook, J.M. Gaziano, D. Gordon, P.M. Ridker, J.E. Manson, C.H. Hennekens, and J.E. Buring. 2005. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 294:56-65.
16. Bergt, C., S. Pennathur, X. Fu, J. Byun, K. O'Brien, T.O. McDonald, P. Singh, G.M. Anantharamaiah, A. Chait, J. Brunzell, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. USA. 10:13032-130327.
17. Zheng, L., B. Nukuna, M.L. Brennan, M. Sun, M. Goormastic, M. Settle, D. Schmitt, X. Fu, L. Thomson, P.L. Fox, et al. 2004. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114:529-541.
18. Otterbein, L.E., M.P. Soares, K. Yamashita, and F.H. Bach. 2003. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol. 24:449-455.
19. Deng, Y.M., B.J. Wu, P.K. Witting, and R. Stocker. Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase- 1. Circulation. 110:1855-1860.
20. Tardif, J.C., G. Cote, J. Lesperance, M. Bourassa, J. Lambert, S. Doucet, L. Bilodeau, S. Nattel, and P. de Guise. 1997. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N. Engl. J. Med. 337:365-372.
21. Tardif, J.C., J. Gregoire, L. Schwartz, L. Title, L. Laramee, F. Reeves, J. Lesperance, M.G. Bourassa, P.L. L'Allier, M. Glass, et al; Canadian Antioxidant Restenosis Trial. 2003. (CART-1) Investigators. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation. 107:552-558.
22. Sawayama, Y., C. Shimizu, N. Maeda, M. Tatsukawa, N. Kinukawa, S. Koyanagi, S. Kashiwagi, and J. Hayashi. 2002. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J. Am. Coll. Cardiol. 39:610-616.
23. Tardif, J.C. 2003. Clinical results with AGI-1067: a novel antioxidant vascular protectant. Am. J. Cardiol. 91(3A):41A-49A.
24. Daugherty, A., J.L. Dunn, D.L. Rateri, and J.W. Heinecke. 1994. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94:437-444.
25. Hazell, L.J., L. Arnold, D. Flowers, G. Waeg, E. Malle, and R. Stocker. 1996. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J. Clin. Invest. 97:1535-1544.
26. Hazen, S.L., and J.W. Heinecke. 1997. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest. 99:2075-2081.
27. Brennan, M.L., M.M. Anderson, D.M. Shih, X.D. Qu, X. Wang, A.C. Mehta, L.L. Lim, W. Shi, S.L. Hazen, J.S. Jacob, et al. 2001. Increased atherosclerosis in myeloperoxidase-deficient mice. J. Clin. Invest. 107:419-430.
28. Hazell, L.J., and R. Stocker. 1997. Alpha-tocopherol does not inhibit hypochlorite-induced oxidation of apolipoprotein B-100 of low-density lipoprotein. FEBS Lett. 414:541-544.